Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 6 Neuroblastoma 2 Meningioma 2 Medulloblastoma 2 Recurrence 1 Lymphoma, Mantle-Cell 1

Interventions

Rituximab 165 Cyclophosphamide 163 fludarabine phosphate 95 Peripheral Blood Stem Cell Transplantation 88 Filgrastim 72 Etoposide 65 Mycophenolic Acid 63 Whole-Body Irradiation 62 Cytarabine 59 Cyclosporine 53 Melphalan 52 Tacrolimus 47 Busulfan 43 Radiotherapy 42 Lenalidomide 42 Bortezomib 40 ibrutinib 39 fludarabine 39 Methotrexate 38 Antilymphocyte Serum 38 Carmustine 37 Bendamustine Hydrochloride 35 Vincristine 33 Doxorubicin 32 Dexamethasone 32 Granulocyte Colony-Stimulating Factor 29 Prednisone 26 Cord Blood Stem Cell Transplantation 25 venetoclax 22 obinutuzumab 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma, Mantle-Cell × 90Y-octreotide, DOTA-Tyr(3)- × Clear all

NCT02488512 2018-03-19

itTRIOlym

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡